EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Tango Therapeutics's enterprise value is $514.29 Mil.
Tango Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $36.53 Mil. Therefore, Tango Therapeutics's EV-to-Revenue for today is 14.08.
The historical rank and industry rank for Tango Therapeutics's EV-to-Revenue or its related term are showing as below:
TNGX'
s EV-to-Revenue Range Over the Past 10 Years
Min: -4.8 Med: 9.17 Max: 67.5
Current: 14.08
During the past 4 years, the highest EV-to-Revenue of Tango Therapeutics was 67.50. The lowest was -4.80. And the median was 9.17.
TNGX's EV-to-Revenue is ranked worse than 62.26% of 1036
companies
in the Biotechnology industry
Industry Median: 7.98
vs TNGX: 14.08
The historical data trend for Tango Therapeutics's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Tango Therapeutics's EV-to-Revenue
For the Biotechnology subindustry, Tango Therapeutics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tango Therapeutics's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Tango Therapeutics's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Tango Therapeutics's EV-to-Revenue falls into.
Tango Therapeutics's current Enterprise Value is $514.29 Mil.
Tango Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $36.53 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tango Therapeutics's share price for today is $7.61.
Tango Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.39.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tango Therapeutics EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Tango Therapeutics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Tango Therapeutics (Tango Therapeutics) Business Description
Tango Therapeutics Inc is a biotechnology company. It is dedicated towards discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
TNGX has been successfully added to your 